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The effect of low- dose tranexamic acid on postoperative 
blood loss in patients treated with clopidogrel and 
aspirin 
 
Abstract 
Background: Clopidogrel in combination with aspirin increases bleeding, allogeneic red 
cell transfusion and reoperation rates after CABG. Tranexamic acid, an antifibrinolytic 
agent, has been approved for use in cardiac surgery to reduce bleeding. In the present 
study, we evaluated the impact of tranexamic acid on the transfusion and post-operative 
blood loss after CABG in patients treated with clopidogrel less than 5 days before surgery. 
Methods: This study was a prospective, randomized, double-blinded clinical trial. Patients 
undergoing on-pump CABG with their last dose of clopidogrel and aspirin less than 5 days 
preoperatively were randomly assigned to receive tranexamic acid (10 mg/kg before 
surgical incision and 10 mg/kg after protamine neutralization) or a corresponding volume 
of saline solution. The incidence of allogeneic red cell transfusion and 48h postoperative 
blood loss were recorded. 
Results: The average volume of blood loss was 776.92±459.81mL for the TXA group and 
1075.00±670.91mL for the control group (P=0.03) in the patients with clopidogrel 
exposure within 48 h before surgery. The average volume of blood loss was not different 
between two groups in the patients with clopidogrel exposure within 5 days before surgery 
and also transfusion rate. 
Conclusion: The result of this study shows that tranexamic acid reduced blood loss in the 
patients with clopidogrel exposure within 48 h before surgery. So, it is better that we use 
tranexamic acid before surgery in all patients. 
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The main factor of myocardial ischemia is coronary atherosclerosis (1). Clopidogrel 
is an inhibitor of platelet aggregation that works by irreversible blockade of adenosine 
diphosphate (2, 3). Clopidogrel has been extensively used in cardiology practice to reduce 
early stent failure and improve outcomes after acute coronary syndrome (4, 5). In addition, 
many patients are receiving long-term clopidogrel with or without aspirin for secondary 
prevention of coronary and cerebrovascular ischemic events. However, some of these 
patients will go on to require an urgent operative procedure (6). Given these urgent 
circumstances, it is not always possible for every patient to withhold his or her 
anticoagulants before surgery (6, 7). Recent studies have shown that clopidogrel treatment 
in combination with aspirin before CABG is associated with increased postoperative 
bleeding, transfusion, and re-exploration rates (2-5). The most common cardiac surgery is 
coronary vessel surgery. 
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The most complication of post cardiac surgery is 
bleeding (8). Some drugs used to decrease post cardiac 
surgery bleeding are aprotinine and aminocaproic acid. 
Tranexamic acid, a serine protease inhibitor with 
antifibrinolytic activity, has successfully been used in 
cardiac and thoracic surgery to reduce overall bleeding and 
transfusion requirements (9, 10). It is a synthetic anti-
fibrinolytic drug that inhibits the lysine-binding site of 
plasmin and plasminogen and reduces fibrinolysis. Several 
studies with TXA have demonstrated a significant reduction 
of perioperative bleeding and the need for transfusions in on-
pump as well as off-pump cardiac surgery (9-11). There is 
only a small number of publications which studied the 
effects of tranexamic acid on patients undergoing CABG 
treated with clopidogrel (12, 13). The aim of this study was 
to determine whether tranexamic acid decreases bleeding and 
transfusion requirements in patients undergoing CABG 
treated with clopidogrel less than 5 days before the 
operation. 
 
 
Methods 
This prospective double-blind randomized clinical trial 
study was done on 120 patients (35-70 years) in Ayatollah 
Rouhani Hospital of Babol University of Medical Sciences 
undergoing primary isolated on-pump CABG, who received 
aspirin and clopidogrel with their last ingestion less than 5 
days preoperatively in 2016. This research project was 
approved by the Research Committee of the Babol 
University of Medical Sciences and by the ethics committee 
of the same university (ethic code: 3012). The study was 
registered in the Iranian registration system 
(IRCT201309125381N8). Written informed consent was 
provided by all the patients. 
 Patients inclusion criteria for the study were those 
without previous cardiac surgery, creatinine>1.5, hematocrit 
less than 33%, platelet count less than 50,000/mL, pump 
time >90 min or blindness of drug. All patients received 
standard anesthetic induction using a combination of 3 
mg/kg of thiopental sodium, 0.1mg/kg of midazolam, 3-
4µg/kg of fentanyl and 1–2% of isoflorane.  Pancuronium at 
a dose of 0.1 mg/kg was used to facilitate orotracheal 
intubation. Intraoperative monitoring included 
electrocardiogram, pulse oximetry, a radial artery catheter to 
measure continuous arterial pressure and a central venous 
pressure line. 
Perioperative management of patients was based 
according to institutional standards by an anesthesiologist 
and cardiothoracic surgeon who were blinded to the study.  
Participants were randomly assigned (1:1) to receive either 
TXA or placebo. An independent statistician was responsible 
for the computerized sequence generation. 
Patients were consecutively randomly allocated to one of 
the following two groups: TXA group (n=60) and control 
group (n=60) (fig 1). Identical syringes of 20 mL labeled 
with the randomization number contained transparent 
solution, either tranexamic acid or saline. Patients separated 
by an anesthesia resident in which these patients received 
tranexamic acid (10 mg/kg before surgical incision and 10 
mg/kg after protamine neutralization) or a corresponding 
volume of saline solution an expert anesthesilogist. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Sampling Diagram of the Study 
 
Surgery was performed through a median sternotomy. 
The distal ascending aorta was annulated, and a two-stage 
venous cannula was inserted into the right atrium and 
inferior vena cava. Anticoagulation for cardiopulmonary 
bypass was achieved with heparin 400 U/kg through a 
venous catheter to activated clotting time (Hemochron Jr.) of 
greater than 480 seconds and monitored during 
cardiopulmonary bypass. At the completion of 
cardiopulmonary bypass, heparin was reversed with 
protamine sulfate (1 mg of protamine for every 100 units of 
heparin). In the absence of perioperative bleeding, patients 
received aspirin (80 mg) six h after surgery. Allogeneic 
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packed red blood cells (PRBC) were added in the CPB if 
hematocrit was <20%. Volume replacement in the ICU was 
administered using normal saline and lactated Ringer’s 
solution. PRBC in the ICU was transfused if the hematocrit 
level was <24%. Fresh frozen plasma was transfused when 
the postoperative international normalization ratio was >1.5 
with excessive bleeding of >200 ml/h for 2 consecutive 
hours. Platelet concentrates were transfused if the platelet 
count was <50000 and bleeding occurred (>200 mL/h for 2 
h). Surgical re-exploration was indicated when chest tube 
drainage was >200 ml/h for 6 consecutive hours or >400 ml 
during the first hour despite normalized activated clotting 
time and global coagulation status. 
The hematocrit level (primary outcome), platelet counts, 
prothrombin time, and activated partial thromboplastin time 
were measured 48h after the surgery. The total number of 
units of packed red blood cells (secondary outcome), fresh 
frozen plasma, and platelets given during the perioperative 
period were recorded, including the number of units given 
during the operation and in the intensive care unit 
postoperatively. The total blood loss was measured from the 
chest tube output starting immediately after closure of the 
chest incision in the operation room and continued until 48 h 
after surgery. In addition, we assessed the demographic 
items, length of mechanical ventilation, length of stay in the 
ICU bedridden and hospital mortality.  
State statistical: About 60 patients  in each group was 
determined on the basis of at least  decreasing 1.5 unit of 
blood in TXA group( 10) with power (80%) and a significant  
level of 0.05 and which assuming  10% possible dropout 
rate. The data were analyzed using the SPSS for windows 
(Version 13.0; Spss inc., Chicago, IL, USA). T-test, repeated 
measurement ANOVA and ANOVA test were used for 
quantitative factors and chi-square test was used for 
qualitative factors. In all cases, a p-value of less than 0.05 
was considered to be statistically significant. 
 
 
Results 
The mean duration from clopidogrel administration to 
CABG was 2.35±0.70 and 2.15±1.70 days for the control 
and clopidogrel groups, respectively. Aspirin was given until 
the day before surgery. The elapsed time between the last 
dose of clopidogrel and the operation was <48 h in 69 of the 
patients and >48 h in 51 of the patients. Baseline characteristics 
and risk factors in two groups were presented in table 1. On 
ICU arrival, the hemoglobin and platelet count significantly 
decreased in comparison to preoperative values in both 
groups (table 2). 
Table1: Baseline Characteristics and risk factors in two 
groups 
 TXA group Control 
group 
Age(years) 58.00±9.66 58.30 ± 11.77 
Weight (kg) 75.80±14.30 74.50 ± 12.50 
Ejection fraction (%) 47.70±8.60 46.00±8.80 
Female sex n (%) 15 (25%) 24 (40%) 
Hypertension 42(70%) 30(50%) 
Diabetes mellitus 36(60%) 18(30%) 
History of myocardial 
infarction 
9(15%) 15(25%) 
Hyperlipidemia 21(35%) 27(45%) 
*Values in table are Mean±SD or n (%) 
 
Table 2: Hematocrit in perioperative period in two 
groups in different times 
 Control 
group 
(n=60) 
TXA 
group 
(n=60) 
P value 
a
 
Hematocrit base (%) 37.89±5.20 37.90±4.60 0.99 
1 hr  postoperative 29.80±3.80 29.90±3.70 0.80 
24 hr 30.43±2.10 29.9±3.8 0.38 
48 hr 28.03±2.30 27.73±3.50 0.58 
P value 
b
 < 0.001 <0.001  
Values in table are Mean± SD       a: The result of the t-test     b: The result 
of the repeated measurement ANOVA –test 
 
Platelet count was slightly higher in the TXA group 
(table 3). The average volume of blood loss was 
776.92±459.81mL for the TXA group and 
1075.00±670.91mL for the control group (P=0.03) in the 
patients with clopidogrel exposure within 48 h before 
surgery. The amount of postoperative bleeding and the need 
for allogeneic transfusions are shown in table 4. There was 
no significant difference in the volume of postoperative 
bleeding between the 2 groups at 48 hours after the 
operation. In this study, 100% of the patients in the two 
groups received blood products during their hospital stay. 
The total use of different blood products are depicted in table 
5. Perioperative transfusion requirements of PRBC, platelet 
and FFP did not differ between groups and there were no 
differences in total doses of heparin (table 5).  
   
Caspian J Intern Med 2019; 10(2):156-161  
Effect of tranexamic acid on postoperative blood loss                                                          159 
Table 3: Platelets in perioperative period in two groups 
in different time 
Platelet Control 
group 
TXA group P-value
a
 
Base 201000±53884 209300±48150 0.37 
1 hr  postoperative 137950±37359 157450±39664 0.06 
24 h postoperative 152950±39325 163250±46670 0.19 
48 h pos-operative 143150±43526 146350±36277 0.66 
P value b <0.001 <0.001  
Values in table are mean± SD       a: The result of the t-test       
b: The result of the repeated measurement ANOVA -test 
Table 4: Comparison of postoperative bleeding in two 
groups 
 Bleeding 
(first 24h) 
Bleeding 
(second 24 h) 
Total 
bleeding(48h) 
TXA 
group(n=60)  
625.00±405.45 197.50±141.24 822.50±449.50 
Control 
group(n=60)   
660.00±405.45 252.50±211.81 912.50±561.22 
P-value * 0.62 0.09 0.33 
*Values in table are Mean±SD         * The result of the t-test 
 
b: The result of the repeated measurement ANOVA –test 
Table 5: Perioperative data in two groups 
 Control group TXA group P value* 
Number of grafts 3.05±0.67 3.10±0.89 0.86 
Surgery (hours) 5.00 ± 0.60 4.95 ± 0.61 0.18 
Cardiopulmonary bypass (minutes) 81.45±27.40 86.95±24.18 0.24 
Aortic cross-clamping (minutes) 48.6±20.90 50.25±15.40 0.62 
Time to extubation (hours) 8.45±3.92 11.05±14.27 0.18 
Length of intensive care unit stay (hours) 78.80±17.98 80.10±28.39 0.78 
Transfusion  (U) 3.60±1.81 3.20±1.67 0.22 
Platelets transfusion 0.8± 1.92 0.85± 1.75 0.66 
                                       Values in table are mean± SD          * the result of the t-test 
 
Discussion 
 Several recent studies have demonstrated that 
clopidogrel within 5 days of CABG is associated with 
increased blood loss, reoperation rates for bleeding, and 
increased use of PRBC and platelets (2-6). A study has 
demonstrated that the reoperation rate in patients undergoing 
CABG increased from 2.3% to 10.4% when the patients 
were treated with aspirin or with the combination aspirin and 
clopidogrel, respectively (14). In a recent study, preoperative 
clopidogrel exposure increased bleeding and transfusion 
requirements in patients receiving on-pump CABG. Wade 
Kang et al. demonstrated that clopidogrel within 3 days 
preoperatively increases the requirement for blood 
transfusion in patients undergoing CABG. Waiting more 
than 3 days decreases blood transfusion requirements. A 
study indicated that tranexamic acid reduced this risk and 
provided protection in the patients with clopidogrel exposure 
within 7 days before surgery. In this study, patients were 
initially loaded with 10 mg.kg of tranexamic acid followed  
by a maintenance dose of 10 mg/kg/h until the end of the 
operation (13). Kang et al. demonstrated that clopidogrel 
within 3 days preoperatively increased blood loss and    
 
transfusion in patients undergoing CABG. Waiting for more 
than 3 days after the last dose of clopidogrel decreased blood 
transfusion and bleeding (15). The rate of blood transfusion 
in the tranexamic acid was less than that in the control group. 
This is not consistent with our finding. The abovementioned 
study used 2 g of tranexamic acid while we used 1 g, yet, the 
results are not much different. The ideal dosage of 
tranexamic acid remains controversial.  
In our study, the need for blood transfusion was not 
significantly different in the two groups, although it was less 
in the tranexamic acid. The possible reason may be the 
flexibility of blood transfusion criteria and dose of TXA.A 
study demonstrated that high dose (30 mg/kg bolus followed 
by 16 mg/kg/h) of TXA is more effective than a low dose 
(10 mg/kg bolus followed by 1 mg/kg/h) to decrease 
transfusion needs, blood loss, and repeat surgery (16).  
Weber et al. indicate that tranexamic acid increased 
arachidonic acid–induced and adenosine diphosphate–
induced platelet aggregation in the patients with dual 
antiplatelet therapy until the day before surgery (9). Indeed, 
plasmin is a key substance in the effect of tranexamic acid on 
platelet function. Plasmin activates the complement cascade 
 Caspian J Intern Med 2019; 10(2):156-161 
160                                                                            Banihashem N, et al. 
which impairs platelet function. Plasmin induces proteolytic 
degradation and redistribution of platelet Ib and IIb/IIIa 
receptors and thereby reduces platelet adhesion and 
aggregation. Tranexamic acid reduces plasmin concentration 
and preventing the binding of plasminogen to fibrin and the 
conversion of plasminogen to plasmin. Probably, tranexamic 
acid and preserve platelet function through a reduction of 
plasmin-induced platelet inhibition (9)..The study contains 
several limitations. First, it was done just in a one center 
study with a relatively small sample size and short follow-up 
period. Second, this study did not examine the impact of 
dose of clopidogrel on bleeding outcome in patients. In 
conclusion, TXA decreases bleeding after CABG in patients 
treated with clopidogrel<48 h before surgery. Further work 
is required to determine the optimal strategy in patients who 
require CABG without clopidogrel and aspirin cessation.   
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